Carbidopa (Lodosyn)

Subscribe to Selected New Research on Carbidopa

541 relevant articles (60 outcomes, 73 trials/studies) found for this Drug

Description: An inhibitor of DOPA DECARBOXYLASE, preventing conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no antiparkinson actions by itself.

Also Known As:

Lodosyn; Carbidopa, (R)-Isomer; Carbidopa, (S)-Isomer; Lodosin; MK-485; MK-486; MK 485; MK 486; MK485; MK486; Methyldopahydrazine; Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Amines: 1234

Catecholamines: 5632

Dihydroxyphenylalanine: 1279

Experts

1.	Nyholm, Dag: 2 articles (03/2008 - 10/2006)
2.	Müller, T: 2 articles (01/2007 - 10/2006)
3.	Woitalla, D: 2 articles (01/2007 - 10/2006)
4.	Muhlack, S: 2 articles (01/2007 - 10/2006)
5.	Kim, Sara Y: 1 article (08/2008)
6.	Donovan, Melissa A: 1 article (08/2008)
7.	Wu, Bai-Lin: 1 article (08/2008)
8.	Jou, Rita L: 1 article (08/2008)
9.	Neilan, Edward G: 1 article (08/2008)
10.	Kang, Peter B: 1 article (08/2008)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/2004 - "The efficacy of domestic drug tremonorm (levadopa-carbidopa) for Parkinson's disease (PD) treatment was studied" 01/01/1973 - "A double-blind controlled study of MK-486 in Parkinson's disease." 10/01/2006 - "Not optimum treated hospitalised patients with Parkinson's disease received the same LD dosage on the first day only with carbidopa (CD) and on the second day with CD and EN (t.i.d.) within a standardised setting" 09/01/1993 - "Ten patients with Parkinson's disease suffering severe motor fluctuations completed a double-blind, placebo-controlled, crossover trial of duodenal infusion of levodopa/carbidopa to determine if this technique improved the duration of functional time by reducing plasma levodopa level variability" 01/01/2007 - "Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease." Order ALL the reference details at left...
2.	Parkinsonian Disorders (Parkinsonism) 02/01/1977 - "Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid]" 10/01/1978 - "Need for uncombined carbidopa to treat parkinsonism." 03/01/1980 - "The new carbidopa-levodopa ratio was 1:4. During 15 months, this treatment produced a moderate decrease in the severity of parkinsonism and a marked decrease in peripheral adverse reactions, without a significant increase in the central adverse effects of levodopa" 01/01/1997 - "Low-dose pergolide together with L-carbidopa is effective in the treatment of parkinsonism without side effects, even in advanced stages of the disease" 07/01/1990 - "1. We have used gait analysis to investigate the efficacy of maintenance therapy with a levodopa/carbidopa combination in patients with idiopathic Parkinsonism, who do not have overt fluctuations in control in relation to administration of medication" Order ALL the reference details at left...
3.	Dyskinesias (Dyskinesia)